[Comparative pharmacological activity of triamcinolone acetonide and of a new topical steroid: amcinonide, after percutaneous or oral administration (author's transl)].
This study was carried out in order to compare the potential anti-inflammatory activity and the level of action of triamcinolone acetonide (Triam. Ac.) and amcinonide (Amc.) after percutaneous administration to animals. Administered per os to rats Amc. is 18 times less active (DI50 1,85 mg . kg-1) on carrageenin plantar edema and 10 times less active (DI50 4,2 mg . kg-1) than Triam Ac. on air pouch granuloma with carrageenin. The potential anti-inflammatory activity at the various levels of tissues under the skin was evaluated with an ointment and a cream containing the two corticosteroïds through three methods: --vasoconstrictor assays on guinea pig showing cutaneous activity; --plantar edema showing subcutaneous activity; --air pouch granuloma showing anti-exsudative activity. The results are as it follows: --vasoconstrictor activity Amc. higher than Triam. Ac.; --plantar edema Amc. equal to Triam Ac.; --air pouch granuloma Am. lesser than Triam. Ac. The two corticoids administered percutaneously show any thymolytic activity on young female rats. Though Amc. is far less active than Triam. Ac. when orally administered, nevertheless it is a powerful dermocorticoïd with a poor systemic activity. Its local effects are less profound than those of Triam. Ac.
D000284:Administration, Oral; D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents; D004487:Edema / Q000517:prevention & control; D008297:Male; D051381:Rats; D014221:Triamcinolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000494:pharmacology*; D014662:Vasoconstrictor Agents
D000893:Anti-Inflammatory Agents; D014662:Vasoconstrictor Agents; D014221:Triamcinolone; C012716:amcinonide; D014222:Triamcinolone Acetonide
Comparaison des effets pharmacologiques de l'acétonide de triamcinolone et d'un nouveu dermocorticoide: l'amcinonide après application par voie percutanée ou administration par voie orale.